Brian Wagner shares LinkedIn commentary on growth strategy, AI, and leadership, often focused on life sciences and medtech. Wagner also describes INIA Biosciences’ work on noninvasive ultrasound therapy for chronic inflammatory disease.
Brian Wagner shares LinkedIn posts about growth strategy, AI, and leadership, often using life sciences and medtech examples.
His posts summarize ideas from consulting research and other speakers, then frame them as concise points for business readers.
He also describes INIA Biosciences’ work on noninvasive ultrasound therapy for chronic inflammatory disease.
The supplied material does not establish a signature book, show, or earlier body of work, so it cannot explain whether one is central to why people search his name.
Wagner’s strength in this sample is turning broad strategy material into short, usable decision frames.
In a post on life sciences growth, he connects AI across research, clinical, manufacturing, and commercial work with platform acquisitions, trial models, and resilience.
In another, he condenses McKinsey’s growth argument into a checklist spanning workflow redesign, scientific capability, expansion, and collaboration between people, AI agents, and robots.
He also shares narrower leadership and foresight ideas, such as matching a foresight style to the decision at hand.
This range makes his feed useful for readers tracking how strategy themes are presented across industries; the posts are summaries and pointers, not evidence that Wagner authored the underlying research or talks.
Brian Wagner's posts return to a handful of priorities: growth as the main source of enterprise value for life sciences and medtech, AI and automation as an operating layer rather than a side project, and combining internal science with outside innovation.
Read more
He also passes along external research and guest talks on where leaders are investing, how to time big decisions, and how leadership and career risk work. Most of his posts summarize or link to someone else's analysis, so his own ideas come through as selection and framing as much as original argument.
Growth is the main lever, not margin
Wagner argues that revenue growth drives far more enterprise value than squeezing margins, citing McKinsey's view that a 1% increase in revenue growth creates roughly eight times the shareholder value of the same gain in margin.
Read more
His reasoning is that growth is the primary driver of value and that margin improvement is the smaller lever. He treats this as the starting point for how leaders should set priorities.
Two posts summarize the same McKinsey analysis. The first lists it first among five points about growth; the second trims everything down to a short restatement led by the same 8x figure.
The argument appears in expanded form and then returns as a tightened repetition, which shows it is a claim he keeps coming back to rather than a one-off share.
Wagner frames AI as something that should run across research and development, clinical work, manufacturing, and commercial operations, not sit in one isolated pilot.
Read more
He ties this to agentic AI, robotics, and workflow redesign, describing future operating models where people, AI agents, and robots work together across whole processes.
He relays SAP's 2026 analysis, which says Johnson & Johnson generated about $500 million in value from roughly 900 AI projects, and separately notes an estimate that AI-powered automation could unlock $2.9 trillion in U.S. economic value by 2030.
Wagner's summaries argue that winners combine internal scientific excellence with external innovation and geographic expansion.
Read more
The point is that medtech and life sciences companies convert breakthroughs into enterprise-wide growth by looking outside their own labs and markets, not by relying on internal research alone.
In his McKinsey summary, external innovation and geographic expansion sit directly alongside commercial modernization as the moves that turn scientific work into growth.
Read where leaders are investing from earnings-call data
Wagner points to tracking what executives say about spending as a way to see shifting priorities across industries and regions.
Read more
He presents the data as a substitute for assumption, letting leaders compare sectors quarter to quarter.
He highlights BCG's CEO Data Point finding that Q3 2026 mentions of growth investments on earnings calls rose 13.5% quarter over quarter, led by energy, insurance, and technology, media, and telecommunications.
Wagner contrasts two ways of looking ahead: a sharp listener who gathers fast insight and a savvy visionary who times big bets.
Read more
His framing is that you pick the style that fits the strategy in front of you rather than treating one as better, so insight turns into action at the right moment.
The post is built around BCG's prompt for finding a foresight approach, pairing fast insight with listening and major bets with vision.
Leadership and career risk, amplified from other thinkers
Wagner shares outside talks on leadership and risk rather than developing his own framework, adding only a short introduction.
Read more
He quotes Anne Morriss on leadership as a practice of imperfect people leading imperfect people, and Molly Graham on the courage to take a step that looks sideways or backward because it is how you learn what you are capable of. The two guests make different points: Morriss on building trust and fixing problems, Graham on non-linear career moves.
Each post pairs a pull quote with a link to the speaker's full talk, so the ideas reach readers mostly through the guests' words.
Health innovation he is connected to: INIA Biosciences
Alongside the strategy commentary, Wagner writes about a company he is tied to.
Read more
He describes INIA Biosciences as advancing drug-free, noninvasive ultrasound therapy to treat chronic inflammatory disease, which gives a concrete health-technology venture next to the broader market themes.
He reports that his team took second place at HBS Foundry Demo Day, pitching live to investors, founders, and advisors against companies from many industries.
This answers what Wagner is building alongside their strategy commentary and gives a newcomer a specific organization to evaluate.
Read more
Wagner writes that their team took second place at HBS Foundry Demo Day and describes INIA Biosciences as advancing drug-free, noninvasive ultrasound therapy to treat chronic inflammatory disease. The post is one of the few direct company and venture signals in the reviewed material.
For brands planning a campaign
A life sciences software company can use this as a concrete health-tech context for a conversation about AI, clinical workflows, or noninvasive treatment. Ask Wagner to explain where software fits into INIA’s development path before proposing a collaboration.
It shows the practical growth agenda Wagner watches in life sciences, with named drivers and a concrete AI-value example.
Read more
Wagner summarizes SAP’s 2026 industry analysis: AI becomes an operating system across R&D, clinical, manufacturing, and commercial; Johnson & Johnson generated $500M in value from roughly 900 AI projects; M&A shifts toward platform acquisitions; hybrid and continuous clinical trials accelerate development by 35–45%; resilience becomes a growth pillar.
For brands planning a campaign
This is a ready-made five-point frame for a collaboration on AI-driven growth strategy. Ask Wagner to adapt it with company-specific examples or to pressure-test the claims against a software buyer’s roadmap.
It is a compact statement of how Wagner translates consulting research into a strategic checklist for medtech and life sciences leaders.
Read more
Wagner distills McKinsey’s view into five points: treat growth as the primary driver of enterprise value, with 1% revenue growth creating about 8× the margin impact; use agentic AI and robotics to redesign workflows; combine internal scientific excellence with external innovation and geographic expansion; modernize commercial strategy; and build operating models where humans, AI agents, and robots collaborate.
For brands planning a campaign
A software company can use this as a discussion hook for workflow redesign or commercial modernization. The strongest collaboration angle is a side-by-side comparison of Wagner’s consulting synthesis with the company’s own AI and automation evidence.
It shows the demand signal Wagner follows and gives a newcomer a quick sense of their data-driven sourcing.
Read more
Wagner highlights BCG’s CEO Data Point finding that Q3 2026 mentions of growth investments on earnings calls rose 13.5% quarter over quarter, led by energy, insurance, and technology, media, and telecommunications.
For brands planning a campaign
This is a data-led entry point for a collaboration about executive priorities. A brand could ask Wagner to connect the earnings-call signal to life sciences or medtech buying behavior, rather than treating it as a general market trend.
It answers what leadership content Wagner shares and gives a newcomer a recognizable external voice in their feed.
Read more
Wagner shares a Molly Graham quote about the courage to take a step sideways or backward and the value of learning how to try, with a link to Graham’s full talk.
For brands planning a campaign
This is a leadership and career-risk theme rather than a growth-strategy piece. It fits an employer-brand, talent, or leadership collaboration if the brief is about how people make non-linear career bets.
It shows how Wagner thinks about matching strategy style to timing, which is useful for readers evaluating their decision process.
Read more
Wagner contrasts two foresight styles: a sharp listener for fast insights and a savvy visionary for timing big bets, and points readers to a BCG tool for finding the style that fits their strategy.
For brands planning a campaign
A consulting or strategy-software brand could collaborate on a foresight assessment, workshop, or decision-timing article. The post already frames the tradeoff, so the collaboration should add a worked example rather than repeat the framework.
It gives a general reader a clear sense of Wagner’s leadership interests and another external thinker they amplify.
Read more
Wagner shares an Anne Morris quote: leadership is a practice of imperfect humans leading imperfect humans, with a link to Morris’s talk on building trust and fixing problems at work.
For brands planning a campaign
This is a culture and trust entry point. A leadership-development or workplace-software brand could use it for a collaboration on problem-solving or trust-building, but it is less directly tied to life sciences growth strategy.
It shows a recurring argument across multiple posts and helps a newcomer see which claims Wagner returns to.
Read more
Wagner posts a shorter version of the same growth argument: 1% revenue growth creates about 8× more shareholder value than the same margin gain; agentic AI, robotics, and automation are reshaping operating models; AI-powered automation could unlock $2.9T in U.S. economic value by 2030; and winners combine scientific excellence with external innovation and geographic expansion.
For brands planning a campaign
This is the most concise version of Wagner’s recurring growth thesis. It works as a thread, carousel, or opening slide, but a brand should verify the underlying sources before republishing the numbers.
Executive priorities through earnings-call signals1
Growth strategy in life sciences and medtech
Several posts frame growth as an enterprise-wide priority for life sciences and medtech leaders, linking it to scientific innovation, commercial strategy, geographic expansion, and operating-model choices.
Read more
One post highlights industry pressures including margin constraints, patent cliffs, and rising research costs; two others summarize McKinsey's view of growth and shareholder value. These are concise summaries and commentary on outside research, not detailed original analyses.
Uses numbered takeaways and connects market-level claims to decisions about growth and operations.
For brands planning a campaign
A brand could assess Wagner for a collaboration that translates broad growth research into questions for life sciences or medtech leaders. A useful brief would ask which growth levers apply to a specific business and what tradeoffs leaders should examine, rather than asking for a generic prediction.
AI appears as a practical business-change theme: posts describe its potential roles across research and development, clinical work, manufacturing, and commercial operations, and connect AI with agents, robotics, and workflow redesign.
Read more
The posts relay claims and examples from SAP and McKinsey materials; they do not show Wagner independently validating those claims.
Condenses external reports into lists of applications and strategic implications.
For brands planning a campaign
For an AI-driven growth campaign, consider a content angle that follows one proposed use case through a life sciences workflow, then asks what would need to change for it to contribute to growth. The existing posts support interest in this subject, but do not establish technical expertise or a track record implementing AI.
A short post contrasts foresight approaches: fast insight is associated with listening, while timing major bets is associated with vision.
Read more
It encourages matching the approach to the strategy, but does not explain the approaches in detail.
Uses a compact contrast to make a strategic choice legible.
For brands planning a campaign
A brand could test a short, decision-focused collaboration on how leaders choose between rapid signal gathering and longer-term bets. The brief should supply a concrete decision scenario; the post alone does not demonstrate a full foresight framework.
Posts share outside talks on fixing workplace problems, building trust, and taking career risks.
Read more
One quotes Anne Morriss on the difficulty of imperfect people leading one another; another highlights Molly Graham's point that a move that looks sideways or backward can still help someone discover their capabilities. These posts indicate interest in leadership and career themes, but offer little original elaboration.
Uses quotations and links to longer talks as entry points.
For brands planning a campaign
Leadership or workplace brands could explore a discussion or short-form series built around a specific management dilemma, with the source talk clearly credited. This is a less directly evidenced fit than life sciences growth or AI strategy, because the posts point readers to others' talks rather than developing Wagner's own framework.
A post about HBS Foundry Demo Day reports that the team took second place and describes INIA Biosciences as advancing noninvasive ultrasound therapy for chronic inflammatory disease.
Read more
This gives a concrete startup and health-innovation example alongside the broader strategy commentary.
Combines an event result with a brief description of a venture's stated approach.
For brands planning a campaign
A health-innovation collaboration could use this post as a starting point for a founder or venture story, provided the brief confirms Wagner's role and the company's current details before making claims. The post documents a team result and a description of the company's work, not Wagner's individual responsibilities.
Executive priorities through earnings-call signals
A post describes BCG's interactive tool for tracking themes in earnings calls and cites a reported quarter-over-quarter rise in mentions of growth investments.
Read more
It presents the tool as a way to compare leadership priorities across sectors and regions.
Uses a reported metric to introduce an external research tool and its possible use.
For brands planning a campaign
A data or research brand could consider a collaboration that turns a specific leadership signal into a question for executives. Any figures or interpretations should be checked against the original research before publication; the post itself does not provide the underlying dataset or analysis.
Wagner's LinkedIn posts reference a small set of organizations: SAP, McKinsey, and BCG as reports and frameworks they summarize for their audience, and INIA Biosciences as a team they describe with 'our' language.
Read more
The posts do not document sponsorship, affiliate, or investment relationships.
SAP
Mention · 2026
Wagner summarized SAP's 2026 life sciences industry analysis, highlighting AI as an operating system, platform-based M&A, and hybrid clinical trials as growth drivers.
Wagner shared McKinsey's growth framework, citing that a 1% revenue increase creates roughly 8x more shareholder value than the same margin gain, and linking to the report.
Wagner posted about BCG's CEO Data Point Interactive, which tracks earnings-call mentions of growth investments, and later shared BCG's guide to strategic foresight styles.
Wagner refers to INIA Biosciences as 'our team' and says 'we're advancing drug-free, noninvasive ultrasound therapy' after the team placed second at the HBS Foundry Demo Day.
Read more
The posts do not state Wagner's exact role or ownership.
Brian Wagner's posts are a practical starting point for life sciences and medtech leaders who want broad strategy signals rather than technical deep dives.
Read more
The most useful path is to begin with the two posts summarizing McKinsey's view that revenue growth creates far more enterprise value than margin gains, then read the SAP 2026 life sciences analysis on AI across research, clinical, manufacturing, and commercial work.
From there, the BCG posts on earnings-call investment signals and strategic foresight show how Wagner frames executive priorities and decision timing.
A separate thread covers leadership and career risk through curated TED talks, and one post describes INIA Biosciences and an HBS Foundry Demo Day result.
Readers looking for adjacent voices can explore Geoffrey Roske for clinical development operations, Aaron Prather for robotics and industrial AI, and Mutembei Kariuki for physical AI and advanced manufacturing.
Roske also writes for people working in life sciences and biopharma, with posts on clinical development challenges and the operational reality of small and mid-size biopharma organizations.
Read more
Like Wagner, Roske turns industry pressures into structured explanations for leaders deciding where to focus.
Roske goes deeper into clinical-trial operations, including enrollment, regulatory complexity, and organ-impairment studies that measure pharmacokinetics. Wagner stays at the level of market-wide growth, AI, and strategy summaries rather than clinical execution detail.
Prather shares Wagner's interest in robotics, automation, and how industrial AI moves from demonstrations into real operations.
Read more
Both use industry analysis and workforce themes to help readers understand where the field is heading.
Prather centers robotics and industrial AI directly, including Women in Robotics Day, engineering career pathways, and A3 Market Intelligence's companies to watch. Wagner approaches automation through life sciences and medtech growth strategy rather than the robotics industry itself.
Kariuki writes about physical AI, edge AI, and advanced manufacturing, which overlaps with Wagner's posts on AI, robotics, and redesigned operating models.
Read more
Both connect industrial technology to how companies run production and operations.
Kariuki shares firsthand event and field observations, including Bay Area physical-AI gatherings and lessons from Japanese manufacturing principles such as Jidoka. Wagner mostly curates and summarizes outside research reports rather than reporting from the field.
Brian Wagner's audience case rests on topic fit, not on documented audience composition.
Read more
The reviewed posts sit squarely in life sciences and medtech growth strategy — AI across R&D and manufacturing, platform M&A, hybrid and continuous clinical trials, resilience as a growth pillar — the same ground as a brief proposing an AI-driven growth strategy collaboration.
The LinkedIn profile showed 3,412 followers when captured on 9 October 2026: a niche professional audience, not a mass-reach placement, and a size that suits a software vendor targeting life-sciences and medtech decision makers rather than broad consumer scale.
No measured audience data came with this material.
There is no geography, age, or gender breakdown, no employer, job function, or seniority data, and no engagement figures (reactions, comments, reposts) for any individual post, so a buyer cannot yet confirm that the people reading are the buyers and technical leaders the campaign needs to reach.
The posting pattern points to an audience of people who follow life-sciences and medtech strategy commentary and curated research from firms such as McKinsey, BCG, and SAP, but that is an inference from what Wagner publishes, not a measurement of who responds to it.
The material also gives no basis for comparing formats or topics: the posts are mostly short text summaries of third-party research, with one first-person update about INIA Biosciences, and none carries performance numbers.
Concrete next step: ask for a LinkedIn audience demographics export (location, industry, company size, seniority) and, if the creator has one, a recent audience survey covering job function and seniority; in the same request, ask for engagement results on recent AI-in-life-sciences posts of comparable length and depth so topics and formats can be compared on actual numbers.
The reviewed posts contain no sponsorship, advertising, or paid-collaboration formats.
Read more
Every post is either commentary on third-party research from BCG, McKinsey, SAP, and TED, or an update about INIA Biosciences.
There is no rate card, media kit, sponsor policy, audience specification, or stated set of deliverables anywhere in the material, so a brand planning a content collaboration on AI-driven growth strategy cannot yet confirm what Wagner offers or what would be required of them.
This is an absence of documented formats in the reviewed material, not a claim that Wagner never accepts sponsorships or paid work.
Treat partnership availability as an open question to resolve directly before committing budget, and preserve the gap rather than assuming a format.
Brief: a life sciences software company wants a content collaboration with Brian Wagner on AI-driven growth strategy.
Read more
This is the strongest match in the reviewed material.
Wagner posts repeatedly on exactly this ground: AI as an operating system across research, clinical work, manufacturing, and commercial operations; workflow redesign using agentic AI and robotics; growth as the primary driver of enterprise value, including the recurring claim that a 1% revenue increase creates roughly 8x the shareholder value of an equivalent margin gain; platform-based M&A; and resilience treated as a growth pillar rather than only a defensive move.
A buyer does not have to infer the fit from a follower count; they can point to specific posts.
Wagner also has a direct stake in the sector through INIA Biosciences, a company the reviewed posts describe as developing noninvasive ultrasound therapy for chronic inflammatory disease, so a discussion about where software sits in life sciences development has a counterpart who already follows the field's growth literature.
Format matches as well as topic.
The posting pattern is short commentary on third-party research from SAP, McKinsey, and BCG, often condensed into numbered takeaways.
That structure suits a collaboration in which Wagner reacts to the vendor's own deployment data and pressure-tests it against the published reports he already cites.
Three limits should shape the brief.
First, reach is niche: the profile showed 3,412 followers when captured on 9 October 2026, and no engagement or demographic data came with the material, so this is a credibility and topic-relevance play, not a scale play, and no reach figure should be promised.
Second, Wagner relays the SAP and McKinsey claims rather than independently validating them, so the collaboration should ask him to interrogate the vendor's numbers, including what did not work, instead of restating a list.
Third, no sponsorship or paid-collaboration format appears anywhere in the reviewed material, and no rate card or media kit was supplied; deliverables, budget, credit, and disclosure terms have to be agreed from scratch rather than assumed.
When to choose a specialist
Brief: a leadership development or employer-brand platform wants a short-form series on non-linear career risk, trust, and fixing problems at work.
Read more
The match looks plausible because two reviewed posts share talks by Molly Graham and Anne Morris.
Graham is quoted on the courage to take a step sideways or backward, and Morris on the difficulty of imperfect people leading imperfect people.
Both posts, however, are quotations plus links to the speakers' full talks; they are pointers to other people's ideas, not a management framework Wagner has developed or tested.
A series built on this brief would largely resell existing talks under a new sponsor's name, with little added interpretation to justify the placement.
The second problem is thematic drift.
Leadership and career risk sit apart from the life sciences, medtech, and growth-strategy material that dominates the reviewed set; the account's throughline is commentary on industry research, not workplace practice.
The audience evidence points the same way: a niche following for life sciences and medtech strategy commentary rather than managers seeking leadership content.
Nothing in the reviewed posts shows Wagner writing about hiring, retention, or team performance in enough depth to carry a platform's campaign.
The decision would change if the platform supplied evidence of a substantial body of original leadership work, a specific management dilemma Wagner is willing to build a framework around, or a role in leadership development that the reviewed material does not show.
Without that, a leadership brief would need a different creator whose own work is the subject, not a reference list of other people's talks.
A worked campaign example
Worked campaign angle for the life sciences software brief, built on the SAP and McKinsey posts and the vendor's own data.
The goal is a three-part credited series in which Wagner applies the growth agenda he already tracks to one named software company's AI deployments, rather than restating industry research.
Part 1, the pressure test.
Wagner takes the five drivers from the SAP 2026 analysis he summarized (AI across R&D, clinical, manufacturing, and commercial; platform M&A; hybrid and continuous clinical trials reported to accelerate development by 35-45%; resilience as a growth pillar) and asks what each would require of a mid-size life sciences company's software stack.
The vendor supplies deployment detail on two or three named workloads, including results and one that underperformed.
The value for a buyer is that a familiar list gets tested against real implementation.
Part 2, the value claim.
A side-by-side piece on the recurring 1% revenue growth versus 8x shareholder value argument Wagner has posted twice, checked against McKinsey's original framing and against the vendor's own revenue and margin experience.
The angle is which AI investments plausibly produce margin or growth, and which are being counted on faith.
Numbers get verified against the source reports before publication, because the posts do not carry the underlying datasets.
Part 3, the demand signal as hook. A short written question-and-answer or moderated discussion, opened with the BCG CEO Data Point figure Wagner cited, that mentions of growth investments on earnings calls rose 13.5% quarter over quarter in Q3 2026, and asks a life sciences technology leader which workflows resist AI and why.
Terms to settle in the brief: Wagner writes and is credited as author; the vendor provides first-party data and approves only factual accuracy of its own figures; sponsorship is disclosed; no follower or reach guarantees are made, given the small audience and absent engagement data; and reuse rights for the pieces are agreed up front.
Choose Roske when the collaboration is about how a life sciences product survives clinical development rather than how a company grows.
Read more
The two reviewed posts are an operational reading of the field: a ranked list of ten challenges facing small and mid-size biopharma for 2025/2026 — trial cost and capital pressure, enrollment shortfalls (only about 30% of trials meet targets), talent shortages, regulatory burden, fragmented data — and a close look at renal and hepatic impairment studies, where design, PK/PD strategy, and enrollment logistics decide whether a program holds up.
Both were published in December 2025.
A software vendor selling into trial design, clinical operations, data integration, or special-population studies has a counterpart whose own examples are the buyer's daily work, and the impairment post ends with an explicit openness to a conversation.
Topic discipline is a better match than Wagner's enterprise-level growth commentary when the audience is clinical operations leads who need to see their own workflow named.
Roske's material is narrower in both direction and format.
The reviewed posts stay inside biopharma clinical development and never address AI as an operating system, platform M&A, commercial strategy, or enterprise value — the ground where Wagner's fit with an AI-driven growth brief comes from.
One post is a ranked list drawn from what the post itself calls publicly available industry sources, so the figures arrive secondhand in the same way Wagner's SAP and McKinsey numbers do; neither creator is presented as publishing original datasets.
Only two posts were available for review, published 9 and 17 December 2025, with no audience, engagement, or commercial-availability information, so selecting Roske trades reach and breadth for operational specificity and must be confirmed against the brief's actual audience.
Choose Prather when the campaign is about industrial automation and robotics adoption rather than life sciences growth.
Read more
The reviewed posts cover two different buyer problems.
One, published 7 October 2026, argues that robotics is spreading into manufacturing, logistics, healthcare, agriculture, and construction, and that the pipeline of engineers, technicians, integrators, and researchers has to start with tools and teams long before college — useful for an employer-brand, workforce, or education brief where the audience includes people deciding whether to enter the field.
The other, published 6 October 2026, introduces an A3 Market Intelligence issue naming eight industrial AI and automation companies to watch over 18 months, framed around four open questions: whether robot foundation models deliver, whether physical AI moves from demos into high-volume operations, whether simulation replaces physical iteration, and whether AI cracks hard logistics workflows.
That is a strong match for an automation vendor or industry body wanting a partner who tracks the commercial landscape and speaks to a technical practitioner audience.
The subject is physical automation, not pharmaceutical or life sciences strategy, so nothing in the reviewed material transfers to a brief about AI in R&D, clinical trials, or commercial operations.
The two posts also do different jobs for a sponsor: the industrial AI post is a deliberately gated promotion for a free download and withholds the eight company names, which suits a lead-generation campaign but gives a partner little quotable analysis to build on, while the robotics-careers post is advocacy for the next generation of workers rather than a product-adjacent argument.
Only two posts were reviewed, dated 6 and 7 October 2026, with no audience or commercial data, so audience overlap with a life sciences buyer is unknown and would need to be established before swapping creators.
Choose Kariuki when the collaboration needs firsthand physical AI and factory-floor experience rather than commentary on published research.
Read more
The reviewed posts are unusually concrete.
One, published 14 November 2025, recounts time spent on advanced manufacturing floors in Japan — Toyota, Honda, Sysmex, HORIBA, data centres, power plants, MES/SCADA/PLC documents — and uses the Toyota principle of Jidoka, machines that detect abnormalities and stop themselves, to frame a real question for the next generation of manufacturing AI, with a stated downtime figure of about $100K per hour.
The other, published 12 November 2025, reports from a Bay Area physical AI event hosted at InOrbit.AI, naming live demos and the people behind them (Parallax Worlds, Reshape Automation, Saphira AI, InOrbit.AI, Robots For Humanity) and describing attendance from Waymo, Bedrock Robotics, Stanford, Toyota Research Institute, Siemens, and IDTA.
For a vendor whose audience values named deployments, ecosystem connections, and a manufacturing vocabulary, this is closer to a practitioner's notebook than to a news summary, and that is a different and often more persuasive offer than Wagner's listed takeaways.
The tradeoff is fit to the buyer's sector and to the format a sponsor can control.
The reviewed posts sit in industrial and physical AI, edge computing, semiconductor, and automotive manufacturing; they do not touch pharmaceutical pipelines, clinical development, pricing, or commercial strategy, which is where the life sciences software brief lives.
They read as personal narrative and event reportage, so a collaboration would lean on Kariuki's own experience and network rather than on a repeatable analytical format a vendor could brief into a series — the opposite of Wagner's numbered-response structure.
Only two posts were reviewed, dated 12 and 14 November 2025, and several companies, events, and roles named in them were not independently verified; no audience or commercial-availability information was supplied.
This profile draws on the full text of eight LinkedIn posts published in 2026, covering life sciences and medtech growth, AI and automation, strategic foresight, leadership commentary, and an INIA Biosciences update.
The linked SAP, McKinsey, BCG, and TED material was not read in full, so figures and framings are presented as Brian Wagner shared them.
A profile capture dated 9 October 2026 recorded 3,412 followers.
No signature book, show, or earlier body of work appears in the supplied material; targeted identity research would be needed to address those name-search questions.
Recent engagement
Across their last 4 LinkedIn posts, the median post got 1 reactions and 0 comments. Checked 2026-11-02.
